Construction of Minigenome Replicon of Nipah Virus and Investigation of Biological Activity
Viruses · 2025
DOI: 10.3390/v17050707 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Fan Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou National Laboratory, Guangzhou 510530, China. Hauptthemen laut MEDLINE: Nipah Virus, Replicon, Genome, Viral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong province, Major Project of Guangzhou National Laboratory.
Abstract (Originalsprache)
Nipah virus (NiV), a highly lethal zoonotic pathogen causing encephalitis and respiratory diseases with mortality rates up to 40–70%, faces research limitations due to its strict biosafety level 4 (BSL-4) containment requirements, hindering antiviral development. To address this, we generated two NiV minigenome replicons (Fluc- and EGFP-based) expressed via helper plasmids encoding viral N, P, and L proteins, enabling replication studies under BSL-2 conditions. The minigenome replicon recapitulated the cytoplasmic inclusion body (IB) formation observed in live NiV infections. We further demonstrated that IB assembly is driven by liquid–liquid phase separation (LLPS), with biochemical analyses identifying the C-terminal N core domain of the N protein, as well as N0 and XD domains and the intrinsically disordered region (IDR) of the P protein, as essential structural determinants for LLPS-mediated IB biogenesis. The targeted siRNA silencing of the 5′ and 3′ untranslated regions (UTRs) significantly reduced replicon-derived mRNA levels, validating the regulatory roles of these regions. Importantly, the minigenome replicon demonstrated sensitivity to type I/II/III interferons and antivirals (remdesivir, azvudine, molnupiravir), establishing its utility for drug screening. This study provides a safe and efficient platform for investigating NiV replication mechanisms and accelerating therapeutic development, circumventing the constraints of BSL-4 facilities while preserving key virological features.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangzhou National Laboratory, Guangzhou 510530, China.
- GMU-GIBH Joint School of Life Science, Guangzhou Medical University, Guangzhou 511436, China.
- Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.
- State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou 510182, China.
- The First Affiliated Hospital, Guangzhou Medical University, Guangzhou 510120, China.
ORCID-Profile: Fan Wang, Jiayi Zhong, Qi Yang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong province
- Major Project of Guangzhou National Laboratory
- Pearl River Talent Recruitment Program
- Basic and Applied Basic Research Projects of Guangzhou Basic Research Program
Zitieren
APA
Wang, F., Chen, R., Zhong, J., Zhou, A., Peng, R., Xue, B., Zhou, Y., Tang, J., Chen, X., & Yang, Q. (2025). Construction of Minigenome Replicon of Nipah Virus and Investigation of Biological Activity. Viruses. https://doi.org/10.3390/v17050707
Vancouver
Wang F, Chen R, Zhong J, Zhou A, Peng R, Xue B, et al. Construction of Minigenome Replicon of Nipah Virus and Investigation of Biological Activity. Viruses. 2025. doi:10.3390/v17050707
BibTeX
@article{Wang2025,
author = {Wang, Fan and Chen, Ruyi and Zhong, Jiayi and Zhou, Anqi and Peng, Ran and Xue, Bao and Zhou, Yuan and Tang, Jielin and Chen, Xinwen and Yang, Qi},
title = {Construction of Minigenome Replicon of Nipah Virus and Investigation of Biological Activity},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17050707}
}
EUVIMED